on Onco-Innovations Limited (isin : CA68237C1059)
Onco-Innovations Collaborates with University of Alberta on Cancer Research
Onco-Innovations Limited has announced a new agreement with the University of Alberta and Cross Cancer Institute to conduct a preclinical study focused on expanding its PNKP Inhibitor technology. The initiative will initially target glioblastoma multiforme (GBM), an aggressive brain cancer with a low five-year survival rate. The study aims to understand the therapeutic potential of PNKP inhibition in tackling treatment-resistant cancers.
Dr. Michael Weinfeld will lead the research project, slated to begin in the third quarter of 2025. The study will evaluate the inhibitor's pharmacological traits and its potential to work alongside standard treatments. Onco-Innovations' CEO, Thomas O'Shaughnessy, emphasized the significance of this preclinical evaluation in broadening the clinical application of their technology.
R. E.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all Onco-Innovations Limited news